JP2004525955A - テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達 - Google Patents

テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達 Download PDF

Info

Publication number
JP2004525955A
JP2004525955A JP2002580910A JP2002580910A JP2004525955A JP 2004525955 A JP2004525955 A JP 2004525955A JP 2002580910 A JP2002580910 A JP 2002580910A JP 2002580910 A JP2002580910 A JP 2002580910A JP 2004525955 A JP2004525955 A JP 2004525955A
Authority
JP
Japan
Prior art keywords
tetracycline
tetracycline compound
release agent
mammal
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002580910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525955A5 (enExample
Inventor
ロバート エイ アシュリー
Original Assignee
コッラジェネックス ファーマシューチカルス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コッラジェネックス ファーマシューチカルス インコーポレイテッド filed Critical コッラジェネックス ファーマシューチカルス インコーポレイテッド
Publication of JP2004525955A publication Critical patent/JP2004525955A/ja
Publication of JP2004525955A5 publication Critical patent/JP2004525955A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2002580910A 2001-04-05 2002-04-05 テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達 Pending JP2004525955A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28185401P 2001-04-05 2001-04-05
PCT/US2002/010748 WO2002083106A1 (en) 2001-04-05 2002-04-05 Controlled delivery of tetracycline compounds and tetracycline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009275764A Division JP2010047617A (ja) 2001-04-05 2009-12-03 テトラサイクリン誘導体の伝達用組成物

Publications (2)

Publication Number Publication Date
JP2004525955A true JP2004525955A (ja) 2004-08-26
JP2004525955A5 JP2004525955A5 (enExample) 2005-12-22

Family

ID=23079059

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002580910A Pending JP2004525955A (ja) 2001-04-05 2002-04-05 テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達
JP2009275764A Pending JP2010047617A (ja) 2001-04-05 2009-12-03 テトラサイクリン誘導体の伝達用組成物
JP2011106231A Pending JP2011157396A (ja) 2001-04-05 2011-05-11 テトラサイクリン誘導体の伝達用組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009275764A Pending JP2010047617A (ja) 2001-04-05 2009-12-03 テトラサイクリン誘導体の伝達用組成物
JP2011106231A Pending JP2011157396A (ja) 2001-04-05 2011-05-11 テトラサイクリン誘導体の伝達用組成物

Country Status (8)

Country Link
US (2) US20040115261A1 (enExample)
EP (2) EP1383483A4 (enExample)
JP (3) JP2004525955A (enExample)
KR (1) KR100982753B1 (enExample)
AU (1) AU2002256092C1 (enExample)
CA (1) CA2447008A1 (enExample)
NZ (1) NZ529308A (enExample)
WO (1) WO2002083106A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516971A (ja) * 2012-04-19 2015-06-18 ガルデルマ エス．アー． ざ瘡の処置方法
JP2016516031A (ja) * 2013-03-15 2016-06-02 メディシス ファーマシューティカル コーポレイション 放出制御医薬剤形

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
JP5586123B2 (ja) * 2003-04-07 2014-09-10 スパーナス ファーマシューティカルズ インコーポレイテッド テトラサイクリンの１日１回製剤
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
AU2004261143B2 (en) * 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1855690B1 (en) * 2005-01-21 2016-06-01 Warner Chilcott Company, LLC A tetracycline metal complex in a solid dosage form
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
EP3260127B1 (en) 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
WO2008121107A1 (en) * 2007-04-02 2008-10-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
PT106679B (pt) * 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP3049096B1 (en) 2013-09-27 2018-12-12 Cornell University Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
WO2015089416A1 (en) 2013-12-12 2015-06-18 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
US20170182117A1 (en) 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
US10576124B2 (en) 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CA2968316A1 (en) 2014-11-19 2016-05-26 Nestle Skin Health Sa Modified release doxycycline composition
EP3316880B1 (en) 2015-07-01 2021-09-01 The Research Foundation for The State University of New York Third generation taxoids and use thereof
EP4000690A1 (en) 2016-05-19 2022-05-25 Stealth BioTherapeutics Inc. Compositions and methods for the prevention and treatment of mitochondrial myopathies
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230323A (ja) * 1990-06-28 1992-08-19 Univ New York State テトラサイクリン含有医薬組成物
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
WO1998008480A2 (en) * 1996-08-30 1998-03-05 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of nitric oxide production
WO2000015235A1 (en) * 1998-09-11 2000-03-23 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
WO2000028983A1 (en) * 1998-11-18 2000-05-25 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethy laminotetra cycline derivatives
JP2000516214A (ja) * 1996-08-01 2000-12-05 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク 化学的に修飾されたテトラサイクリンによる創傷治癒の促進

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA843403A (en) * 1970-06-02 E. Gaunt William Sustained release medicinal tablets
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US5589470A (en) * 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4666897A (en) * 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
IL95423A (en) * 1989-09-21 1994-11-11 American Cyanamid Co Pulsatile once-a-day delivery systems for minocycline
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5223248A (en) * 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
US5770588A (en) * 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043231A (en) * 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827503A (en) * 1996-08-08 1998-10-27 Collagenex Pharmaceuticals, Inc. Method and composition for treating periodontitis
JPH10190373A (ja) * 1996-12-20 1998-07-21 Fujitsu Ltd 増幅回路
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5792446A (en) * 1997-02-18 1998-08-11 Collagenex Pharmaceuticals, Inc. Delivery system for administering dentin-hypersensitivity-ameliorating compositions
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5753711A (en) * 1997-03-18 1998-05-19 Collagenex Pharmaceuticals, Inc. Method for treatment of H. pylori
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US5908838A (en) * 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
ATE319456T1 (de) * 1998-05-08 2006-03-15 Univ Miami Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
US6143506A (en) * 1998-08-13 2000-11-07 The Research Foundation Of State Of Ny Diagnostic method for detection of periodontitis or peri-implantitis
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
JP2002525299A (ja) * 1998-09-28 2002-08-13 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク 新規白内障形成抑制剤
US6914057B1 (en) * 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) * 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6217904B1 (en) * 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6638532B2 (en) * 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
AU2001239841B2 (en) * 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2003230935B2 (en) * 2002-04-16 2008-08-07 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US7211627B2 (en) * 2003-02-28 2007-05-01 Zeon Corporation Elastomer composition and pressure-sensitive adhesive compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230323A (ja) * 1990-06-28 1992-08-19 Univ New York State テトラサイクリン含有医薬組成物
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
JP2000516214A (ja) * 1996-08-01 2000-12-05 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク 化学的に修飾されたテトラサイクリンによる創傷治癒の促進
WO1998008480A2 (en) * 1996-08-30 1998-03-05 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of nitric oxide production
WO2000015235A1 (en) * 1998-09-11 2000-03-23 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
WO2000028983A1 (en) * 1998-11-18 2000-05-25 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethy laminotetra cycline derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516971A (ja) * 2012-04-19 2015-06-18 ガルデルマ エス．アー． ざ瘡の処置方法
JP2016516031A (ja) * 2013-03-15 2016-06-02 メディシス ファーマシューティカル コーポレイション 放出制御医薬剤形
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms

Also Published As

Publication number Publication date
EP1383483A1 (en) 2004-01-28
KR20040002896A (ko) 2004-01-07
WO2002083106A1 (en) 2002-10-24
KR100982753B1 (ko) 2010-09-16
NZ529308A (en) 2005-03-24
CA2447008A1 (en) 2002-10-24
EP2311440A1 (en) 2011-04-20
AU2002256092C1 (en) 2009-10-15
US20110262542A1 (en) 2011-10-27
EP1383483A4 (en) 2006-08-09
US20040115261A1 (en) 2004-06-17
AU2002256092B2 (en) 2007-05-31
JP2011157396A (ja) 2011-08-18
JP2010047617A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
AU2002256092C1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
AU2002256092A1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
AU754515B2 (en) Method of using tetracycline compounds to enhance interleukin-10 production
US20220016041A1 (en) Once Daily Formulations Of Tetracyclines
NZ519575A (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
NZ538198A (en) Method for reducing C-reactive protein (CRP) levels by administering a non-antibacterial tetracycline formulation or a low dose of an antibacterial tetracycline formulation
WO2004054509A2 (en) Tetracyclines as anti-fungal agents for treatment of ringworm

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100324

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111114